From disease to treatment: from rare skeletal disorders to treatments for osteoporosis (Q26764854)

21 June 2017

4 references

13 March 2019

24 March 2019

20 June 2019

19 September 2019

From disease to treatment: from rare skeletal disorders to treatments for osteoporosis (English)

1 reference

biomedical investigative technique

21 June 2017

4 references

13 March 2019

24 March 2019

20 June 2019

19 September 2019

4 references

13 March 2019

24 March 2019

20 June 2019

19 September 2019

1 reference

19 September 2019

Natasha M Appelman-Dijkstra

series ordinal

1 reference

21 June 2017

Socrates E Papapoulos

series ordinal

1 reference

21 June 2017

language of work or name

English

0 references

publication date

18 February 2016

1 reference

21 June 2017

1 June 2016

4 references

13 March 2019

24 March 2019

20 June 2019

19 September 2019

5 references

21 June 2017

13 March 2019

24 March 2019

20 June 2019

19 September 2019

1 reference

21 June 2017

1 reference

21 June 2017

page(s)

414-426

1 reference

Creative Commons Attribution 4.0 International

21 June 2017

4 references

13 March 2019

24 March 2019

20 June 2019

on focus list of Wikimedia project

19 September 2019

copyrighted

0 references

ScienceSource

0 references

cites work

Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Bone mineral density in sclerosteosis; affected individuals and gene carriers

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Osteopetrosis with syndactyly; a morphological variant of Albers-Schönberg's disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

High bone density due to a mutation in LDL-receptor-related protein 5

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Linkage of pycnodysostosis to chromosome 1q21 by homozygosity mapping

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Intracellular machinery for matrix degradation in bone-resorbing osteoclasts

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Molecular and clinical analysis in a series of patients with Pyknodysostosis reveals some uncommon phenotypic findings

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Novel approaches to the treatment of osteoporosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women: results of a two-year placebo-controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Cathepsin K analysis in a pycnodysostosis cohort: demographic, genotypic and phenotypic features

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

New therapeutics for osteoporosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Status of drug development for the prevention and treatment of osteoporosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Targeted deletion of Sost distal enhancer increases bone formation and bone mass

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Inhibition of cathepsin K for treatment of osteoporosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Clinical and animal research findings in pycnodysostosis and gene mutations of cathepsin K from 1996 to 2011

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Bone density, strength, and formation in adult cathepsin K (-/-) mice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Are nonresorbing osteoclasts sources of bone anabolic activity?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Lysosomal cysteine proteases regulate antigen presentation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Glucocorticoids are not always deleterious for bone

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation.

31 May 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0888-7

Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0888-7

Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0888-7

Are cathepsin k inhibitors just another class of anti-resorptives?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0888-7

Odanacatib increases mineralized callus during fracture healing in a rabbit ulnar osteotomy model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0888-7

Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0888-7

Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0888-7

Sclerostin deficiency is linked to altered bone composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0888-7

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0888-7

Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0888-7

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0888-7

Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0888-7

Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0888-7

Romosozumab in postmenopausal women with low bone mineral density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0888-7

The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0888-7

Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0888-7

Effects of Odanacatib on the Radius and Tibia of Postmenopausal Women: Improvements in Bone Geometry, Microarchitecture, and Estimated Bone Strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0888-7

Odanacatib Restores Trabecular Bone of Skeletally Mature Female Rabbits With Osteopenia but Induces Brittleness of Cortical Bone: A Comparative Study of the Investigational Drug With PTH, Estrogen, and Alendronate

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879160

Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K

28 November 2018

1 reference

12 December 2020

High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K

1 reference

12 December 2020

The collagenolytic activity of cathepsin K is unique among mammalian proteinases

1 reference

12 December 2020

Single- and Multiple-Dose Randomized Studies of Blosozumab, a Monoclonal Antibody Against Sclerostin, in Healthy Postmenopausal Women

1 reference

12 December 2020

Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis

1 reference

12 December 2020

The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking

1 reference

12 December 2020

An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris

1 reference

12 December 2020

2 cases of a condensing osseous disease: pynodysostosis

1 reference

12 December 2020

Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study

1 reference

12 December 2020

Anabolic bone therapies in 2014: New bone-forming treatments for osteoporosis

1 reference

12 December 2020

Bone matrix quality after sclerostin antibody treatment

1 reference

12 December 2020

Effects of eight-month treatment with ONO-5334, a cathepsin K inhibitor, on bone metabolism, strength and microstructure in ovariectomized cynomolgus monkeys

1 reference

12 December 2020

Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits

1 reference

12 December 2020

Tetracycline-based Study of Bone Dynamics in Pycnodysostosis

1 reference

12 December 2020

Study of immunoelectron microscopic localization of cathepsin K in osteoclasts and other bone cells in the mouse femur

1 reference

12 December 2020

10.1007/S12020-016-0888-7

Identifiers

DOI

1 reference

Dimensions Publication ID

21 June 2017

1042849606

0 references

PMC publication ID

4879160

0 references

1 reference